Sutro Biopharma, Inc. · GETTEX:S090

Sutro Biopharma, Inc. financial statements

Sutro Biopharma, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue102.5M62.0M153.7M67.8M61.9M42.7M42.7M38.4M51.7M59.7M
Cost of revenue7.32M7.22M6.82M8.29M9.77M77.0M65.6M54.3M51.9M43.5M
Gross profit95.2M54.8M146.9M59.5M52.1M-34.2M42.7M-15.8M-156.0K16.2M
Research and development166.4M252.0M180.4M137.2M104.4M77.0M65.6M54.3M54.6M43.5M
Selling, general and administrative41.0M48.5M62.6M59.5M56.0M36.8M32.6M21.4M16.4M14.8M
Operating income-158.4M-238.5M-89.3M-128.9M-98.5M-71.1M-55.5M-37.2M-19.3M1.36M
Depreciation and amortization7.32M7.22M6.82M5.69M4.84M4.30M4.78M4.54M4.99M5.66M
EBITDA-151.0M-231.2M-82.5M-123.3M-93.7M-66.8M-50.7M-32.7M-14.3M7.03M
Interest expense38.2M31.1M1.30M2.40M2.60M2.30M1.10M1.62M612.0K0
Income before tax-191.2M-225.1M-88.6M-116.7M-105.5M-32.0M-55.7M-35.3M-19.7M1.70M
Income tax-93.0K2.36M18.2M2.50M0103.0K00087.0K
Net income-191.1M-227.5M-106.8M-119.2M-105.5M-32.1M-119.2M-35.3M-19.7M1.70M
Earnings per share, basic-22.49-29.40-1.78-2.35-2.29-0.99-2.43-6.13-43.950.00
Earnings per share, diluted-22.49-29.40-1.78-2.35-2.29-0.99-2.43-6.13-43.950.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents58.1M190.3M69.3M47.3M30.4M206.2M4.96M125.3M22.0M11.6M
Short-term investments83.3M126.6M264.4M255.1M130.3M120.3M112.9M79.2M035.9M
Receivables3.98M8.62M36.1M7.12M12.5M5.56M6.30M2.49M1.62M577.0K
Inventory1-11.7M11
Current assets150.9M343.3M421.5M353.2M218.5M378.2M128.6M209.9M25.6M49.7M
Property, plant and equipment10.6M18.2M21.9M24.6M22.6M12.9M9.63M10.9M14.0M18.7M
Total assets173.8M387.2M470.7M406.9M341.4M394.1M156.4M223.1M40.8M69.3M
Accounts payable7.57M10.5M9.44M4.80M6.01M5.54M5.58M3.06M2.90M3.39M
Current liabilities75.1M131.9M93.7M66.5M41.7M29.6M33.0M36.4M32.0M50.2M
Long-term debt03.77M15.7M24.5M8.88M10.0M1.71M1.19M
Total debt15.7M23.2M4.06M16.3M25.1M24.5M8.88M14.7M16.3M1.19M
Total liabilities306.3M342.6M321.1M189.9M88.8M62.1M58.6M91.6M47.3M160.2M
Shareholders' equity-132.5M44.6M149.6M217.0M252.6M332.0M97.8M131.5M-109.0M-90.9M
Shares outstanding8.58M8.31M61.0M57.5M46.3M45.8M23.1M22.8M465.3K23.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-177.2M-191.5M-111.6M3.55M-81.7M-67.8M-65.0M12.7M-37.1M-13.2M
Capital spending-1.70M-3.10M-4.32M-7.86M-15.3M-7.13M-3.48M-1.56M-3.32M-4.39M
Free cash flow-178.9M-194.6M-115.9M-4.31M-97.0M-74.9M-68.5M11.1M-40.4M-17.5M
Cash from investing45.0M218.5M-3.92M-35.0M-97.3M604.0K-51.1M-80.2M32.6M9.59M
Cash from financing44.0K94.1M137.6M48.3M3.26M269.2M-4.18M170.8M14.6M177.0K
Dividends paid-463.0K-314.0K-297.0K
Share buybacks-490.0K-463.0K-7.00K-314.0K-327.0K84.4M15.1M184.0K
Change in cash-132.2M121.0M22.0M16.8M-175.7M202.0M-120.3M103.3M10.2M-3.38M